Committed to sharing our science

Committed to sharing our science

scientist testing potential medicines

316 results available

A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin

International Journal of Toxicology

Pugsley, MK et al

March 20, 2025
Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten

Clinical Pharmacokinetics

Xu, D et al

February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics

Journal of the American College of Cardiology: Heart Failure

Garcia-Pavia, P et al

February 3, 2025
Changes in EQ-5D-5L with Aficamten in Obstructive Hypertrophic Cardiomyopathy (oHCM): the SEQUOIA-HCM Trial

Poster, AHA 2024

Schulze, C et al.

November 18, 2024
Modifiability of Post-Exercise Oxygen Uptake Recovery Patterns: A Substudy of the SEQUOIA-HCM Randomized Trial

Oral Presentation, AHA 2024

Lewis, G et al.

November 17, 2024